4//SEC Filing
Hants Brandon 4
Accession 0001209191-23-051228
CIK 0001801777other
Filed
Oct 1, 8:00 PM ET
Accepted
Oct 2, 7:10 PM ET
Size
7.6 KB
Accession
0001209191-23-051228
Insider Transaction Report
Form 4
Hants Brandon
VP, Finance & Bus. Ops.
Transactions
- Award
Common Stock
2023-09-28+491,111→ 523,326 total - Sale
Common Stock
2023-09-29$0.16/sh−107,540$17,045→ 415,786 total
Footnotes (3)
- [F1]The reported shares are represented by restricted stock units, or RSUs. 443,055 RSUs vested upon signing of the Agreement and Plan of Merger dated as of September 21, 2023, among Cyclo Therapeutics, Inc., a Nevada corporation, Cameo Merger Sub, Inc., a Delaware corporation and the Issuer (the "Merger Agreement"). The remaining 443,056 RSUs vest as to 50% on the date that is five trading days following the filing of the proxy/prospectus relating to stockholder approval of the merger contemplated by the Merger Agreement (the "Form S-4") and 50% on the date the Form S-4 is declared effective by the SEC.
- [F2]Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of RSUs. This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person.
- [F3]A portion of these securities are RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
Documents
Issuer
Applied Molecular Transport Inc.
CIK 0001801777
Entity typeother
Related Parties
1- filerCIK 0001813219
Filing Metadata
- Form type
- 4
- Filed
- Oct 1, 8:00 PM ET
- Accepted
- Oct 2, 7:10 PM ET
- Size
- 7.6 KB